Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 101 related to Bent: Brief communication: better ways to question patients about adverse medical events:.... (0.11 sec) 

Brief communication: better ways to question patients about adverse medical events: a …

- annals.org [PDF] 
S Bent, A Padula, AL Avins - Annals of internal medicine, 2006 - Am Coll Physicians
Page 1. Brief Communication: Better Ways To Question Patients about Adverse
Medical Events A Randomized, Controlled Trial Stephen ...
Cited by 33 - Related articles - BL Direct - All 4 versions

[CITATION] Adverse events: the more you search, the more you find.


JP Ioannidis, CD Mulrow, SN Goodman - Annals of internal medicine, 2006 - ncbi.nlm.nih.gov
1: Ann Intern Med. 2006 Feb 21;144(4):298-300. Comment on: Ann Intern Med. 2006
Feb 21;144(4):257-61. Ann Intern Med. 2006 Feb 21;144(4):306-7. ...
Cited by 29 - Related articles - BL Direct - All 2 versions

Dealing with a deluge of data: An assessment of adverse event data on North Central …

- ascopubs.org
MR Mahoney, DJ Sargent, MJ O'Connell, RM … - Journal of Clinical Oncology, 2005 - jco.ascopubs.org
PURPOSE: Adverse events (AEs) are monitored in clinical trials for patient
safety, to satisfy reporting requirements, and develop safety profiles.
Recently, much attention has been placed on the reporting of serious AEs ...
Cited by 14 - Related articles - All 9 versions

[CITATION] Oupatient gatifloxacin therapy and dysglycaemia in older patients


LY Park-Wyllie, DN Juurlink, A Kopp… - N. Engl. J. Med, 2006
Cited by 3 - Related articles

[CITATION] The rofecoxib case. What have we learnt from Vioxx


HM Krumholz, JS Ross, AH Presler, DS … - BMJ, 2007
Cited by 3 - Related articles

IOM: overhaul drug safety monitoring


BM Kuehn - JAMA, 2006 - Am Med Assoc
The changes urge the FDA to adopt a "lifecycle" approach to monitoring drug
safety, paying close attention to the safety of the drug from development until
the end of a drug's useful life. Fifteen experts from a variety of ...
Cited by 4 - Related articles - All 2 versions

[CITATION] Risk management planning: time to deliver


P Waller, UK Southampton - Pharmacoepidemiology and Drug Safety, 2006 - interscience.wiley.com
It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ...
Cited by 5 - Related articles - BL Direct

[CITATION] Augmentin-associated jaundice.


JA Thomson, CK Fairley, JJ McNeil, P Purcell - The Medical journal of Australia, 1994 - ncbi.nlm.nih.gov
1: Med J Aust. 1994 Jun 6;160(11):733-4. Augmentin-associated jaundice.
Thomson JA, Fairley CK, McNeil JJ, Purcell P. Publication ...
Cited by 5 - Related articles - BL Direct - All 2 versions

[CITATION] Adverse drug reaction reporting: attitudes of Australian hospital pharmacists and doctors


Y Nita, KT Batty, RJ Plumridge - J. Pharm. Pract. Res, 2005
Cited by 5 - Related articles

Widespread Hyoscine Hydrobromide Toxicity Due to Contract Manufacturer Malpractice: …

- adisonline.com [PDF] 
J McEwen, BR Thompson, PM Purcell, LF … - Drug safety, 2007 - ingentaconnect.com
An outbreak of hyoscine hydrobromide toxicity was detected through the Abstract
Australian pharmacovigilance system. The unexpectedly wide variation in hyos-
cine hydrobromide content between individual tablets within single packets ...
Cited by 6 - Related articles - BL Direct - All 7 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google